37 reports

  • BPI-7881A - DRUG PROFILE

The drug candidate acts by blocking the histamine receptors and prevents the excess mucus production associated with ocular allergy.

  • Drug Development
  • Ear Disease
  • Molecular Diagnostics
  • Therapy
  • Sensorion S.A.

Hoffmann-La Roche Ltd ## ## ## ## ## AnaptysBio Inc ## ## ## ## ## Food Allergy Research & Education Inc ## ## ## ## ## Novartis AG ## ## ## ## ## Droege International Group AG ## ## ## ## ## Allertein Therapeutics LLC ## ## ## ## ## Allergy Therapeutics

  • Drug Development
  • Medical Biotechnology
  • World
  • Product Initiative
  • Aimmune Therapeutics, Inc.
  • THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2017)

The company' s product portfolio includes innovative technologies for mass spectrometry, chromatography, elemental analysis, molecular spectroscopy, cell culture analysis, allergy testing, drugs-of-abuse testing, therapeutic drug monitoring, microbiology, anatomical pa

  • Drug Development
  • North America
  • United States
  • Forecast
  • Bruker Corporation
  • DISSOLVING MICRONEEDLES - PRODUCT DESCRIPTION

Other revenue reached ™ ## million from ™ ## million in 2017, due to the one-time other revenue in 2017 of ™ ## million for out-licensing of the overthe-counter allergy drug Xyzal® (levoceterizine) in the U. S.

  • Drug Development
  • Pharmaceutical
  • Therapy
  • United States
  • Company
  • CLINICAL TRIAL PROFILE SNAPSHOTS

DRUG HYPERSENSITIVITY REACTIONS THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2019* PROMINENT DRUGS DRUG HYPERSENSITIVITY REACTIONS THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2019*

  • Clinical Trial
  • Drug Development
  • Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 330 Trial Title

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Development
  • Hospital
  • Pharmaceutical
  • World
  • ACT-774312 - DRUG PROFILE

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Asthma
  • Drug Development
  • United States
  • World
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

WRINKLES THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2018* PROMINENT DRUGS WRINKLES THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2018* WRINKLES THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL

  • Clinical Trial
  • Drug Development
  • Therapy
  • World
  • Product Initiative

The drug candidate is a human immunoglobulin monoclonal antibody targeting eotaxin-##.

  • Drug Development
  • Eye Disease
  • United States
  • Product Initiative
  • Aldeyra Therapeutics, Inc.
  • SMART CONTACT LENSES - PRODUCT DESCRIPTION

PDR## (PD-## Antagonist) received orphan drug designation from FDA for treatment of neuroendocrine tumors.

  • Drug Development
  • Medical Device
  • United States
  • Company
  • Valeant Pharmaceuticals International, Inc.
  • DISSOLVING MICRONEEDLES - PRODUCT DESCRIPTION

One patch was loaded with drug-containing nanoparticles, and the other patch held no drugs.

  • Clinical Trial
  • Drug Development
  • United States
  • Company
  • Aequus Pharmaceuticals Inc.

Allergy Therapeutics Plc (Allergy Therapeutics) is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention.

  • Drug Development
  • United Kingdom
  • Company
  • M&A
  • Ergomed plc

GAAP measures, see " Non-GAAP Financial Measures" and Tables ##, ## and ##.

  • Drug Development
  • United States
  • Company
  • M&A
  • AMRI
  • SMART CONTACT LENSES - PRODUCT DESCRIPTION

The drug-polymer film slows the drug coming out of the lens.

  • Clinical Trial
  • Drug Development
  • Eyewear
  • Ophthalmology
  • Valeant Pharmaceuticals International, Inc.
  • 5. All the trials included are unique trials.

ALLERGIES THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2018* PROMINENT DRUGS ALLERGIES THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2018* ALLERGIES THERAPEUTICS CLINICAL TR

  • Clinical Trial
  • Drug Development
  • Pharmaceutical
  • Japan
  • World

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Drug Development
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative

Subjects will orally take study drug once daily in the evening for one month.

  • Drug Development
  • Eye Disease
  • Ophthalmology
  • United States
  • Advanced Cell Technology, Inc.
  • 5. All the trials included are unique trials.

TYPE I HYPERSENSITIVITY THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2018* PROMINENT DRUGS TYPE I HYPERSENSITIVITY THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2018* TYPE I HYPERSENSITIVITY THERAPEUT

  • Allergy
  • Clinical Trial
  • Drug Development
  • Pharmaceutical
  • World
  • Clinical Trial profile. 307 Trial Title
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

DRUG/ MOLECULE REFERS TO PRIMARY INTERVENTION ONLY. ##.

  • Clinical Trial
  • Drug Development
  • Molecular Diagnostics
  • Pharmaceutical
  • World

Sanofi also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women' s health; and vitamins, minerals and supplements.

  • Drug Development
  • Hospital
  • Immunotherapy
  • Therapy
  • MediciNova, Inc.
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

DRUG/ MOLECULE REFERS TO PRIMARY INTERVENTION ONLY. ##.

  • Allergy Drug
  • Drug Development
  • Pharmaceutical
  • Respiratory Disease
  • World
  • ACT-774312 - DRUG PROFILE

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Asthma
  • Drug Development
  • United Kingdom
  • World
  • Product Initiative
  • THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2016)
  • 12.5 THERMO FISHER SCIENTIFIC INC.

THE HIGH COST AND LONG DURATION OF DRUG DEVELOPMENT ARE COMPELLING PHARMACEUTICAL COMPANIES TO REVISE THEIR R& D EXPENDITURE. ##. ##. ##. ## THE CONVENTIONAL METHOD OF TOXICITY STUDIES INVOLVES THE SCREENING OF LARGE LIBRARIES IN SEARCH OF POTENTIAL DRUG CANDIDA

  • Drug Development
  • Market Size
  • Becton Property Group
  • Danaher Corporation
  • GE Healthcare Limited
  • MICROCYN ALLERGEN SHIELD HYDROGEL - PRODUCT DESCRIPTION

RESULTS WERE PUBLISHED IN THE INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY.

  • Anesthetics
  • Clinical Trial
  • Drug Development
  • Pharmaceutical
  • Opiant Pharmaceuticals, Inc.

The drug candidate is a ##-imino-##, ##, ##-thiadiazole derivative.

  • Drug Development
  • Gene Therapy
  • Pharmaceutical
  • Therapy
  • Amarantus BioScience Holdings, Inc.

EDEMA THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2017* PROMINENT DRUGS EDEMA THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2017* EDEMA THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS B

  • Clinical Trial
  • Drug Development
  • Therapy
  • World
  • Product Initiative

Drug/ Molecule refers to Primary Intervention only. ##.

  • Drug Development
  • Ophthalmic Solution
  • Pharmaceutical
  • World
  • Product Initiative
  • SMART CONTACT LENSES - PRODUCT DESCRIPTION

As of July ##, 2016, the new centralized Technical Operations and integrated Drug Development organizations are operational.

  • Drug Development
  • Medical Device
  • United States
  • Company
  • Valeant Pharmaceuticals International, Inc.
  • 5. All the trials included are unique trials.

HYPERSENSITIVITY THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2017* PROMINENT DRUGS HYPERSENSITIVITY THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2017* HYPERSENSITIVITY THERAPEUTICS CLINICAL TRIALS,

  • Clinical Trial
  • Drug Development
  • Pharmaceutical
  • Japan
  • World

CY-## - DRUG PROFILE DORA-## - DRUG PROFILE DRGT-## - DRUG PROFILE DRUG FOR INSOMNIA - DRUG PROFILE DRUGS TO INHIBIT ANGIOTENSIN II RECEPTOR TYPE ## FOR INSOMNIA - DRUG PROFILE EVT-## - DRUG PROFILE Drug Name C

  • Drug Development
  • Sleep Aid
  • United States
  • World
  • Product Initiative